ArticleIn vivo (Athens, Greece)
Successful Retreatment of Chronic Hepatitis C Virus Genotype 1A Infection With Glecaprevir/Pibrentasvir in a Pediatric Patient With Developmental Disorder.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimAlthough direct-acting antiviral (DAA) therapy is now available for pediatric patients with chronic hepatitis C virus (HCV) infection, the challenges associated with its use are similar to those observed in adults. In pediatric patients with chronic hepatitis C virus genotype 1A infection, the granular formulation of glecaprevir/pibrentasvir (GLE/PIB) can make oral administration difficult. CASE REPORT: We report a case of infection in a child with developmental disorder who achieved sustained virologic response after retreatment with a 12-week course of GLE/PIB, following initial treatment failure with GLE/PIB. However, through mother-pharmacy department collaboration, treatment efficacy was achieved by extending the GLE/PIB treatment period in our case, despite initial treatment failure and recurrence.
conclusionAlthough rare, this single case suggests that prolonged GLE/PIB therapy may be effective following failure with 8-week GLE/PIB therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.